Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Potential advantages of mAb
- Challenges for mAb
- Antibody based therapeutic proteins
- Immunoligand
- Attributes of immunoligands
- Immunoligands can be readily designed
- Creation of Ig-based fusion proteins
- Creation of cytolytic human IL-2/Fc fusion protein
- Creation of non-cytolytic IL-2/Fc fusion protein
- CTLL-2 proliferation assay
- Altering biological functions of Fc region (1)
- Altering biological functions of Fc region (2)
- IL-2/Fc circulating half-life
- Non-cytolytic IL-2/Fc fusion protein
- Vaccine trial design
- Vaccine trial results
- Cytolytic IL-2/Fc blocks autoimmunity
- Creating cytolytic IL-15R antagonist fusion protein
- IL receptors subunits
- Role of glutamines found in T cells growth factors
- Creating cytolytic IL-15 mutant/Fc fusion protein
- Mutant IL-15/Fc inhibits IL-15 mediated cell growth
- Creating transplant tolerance
- Application of immunoligand
- Challenges for immunoligands
Topics Covered
- Potential advantages of mAB
- Challenges for mAB
- Antibody based therapeutic proteins
- Attributes of immunoligands
- Creation of Ig-based fusion proteins
- Non-cytolytic IL-2/Fc fusion protein
- Vaccine trial design
- Creation of cytolytic IL-15R antagonist fusion protein
- Application of immunoligand: immunogen for mAB production, to stain the cognate ligand, to identify cell surface cognate ligands via immunoprecipitation, to create long lived proteins to test the function of the targeting ligand in vivo and to modulate immune responses
- Challenges for immunoligands
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Strom, T. (2007, October 1). Novel immunotherapeutic proteins: immunoligand [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/BVDT9210.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Terry Strom has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.